Progyny (PGNY) Revenue & Revenue Breakdown
Progyny Revenue Highlights
Latest Revenue (Y)
$1.09B
Latest Revenue (Q)
$304.09M
Main Segment (Y)
Fertility benefit services revenue
Progyny Revenue by Period
Progyny Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.09B | 38.34% |
| 2022-12-31 | $786.91M | 57.19% |
| 2021-12-31 | $500.62M | 45.17% |
| 2020-12-31 | $344.86M | 50.15% |
| 2019-12-31 | $229.68M | 117.92% |
| 2018-12-31 | $105.40M | 116.94% |
| 2017-12-31 | $48.58M | - |
Progyny generated $1.09B in revenue during NA 2023, up 38.34% compared to the previous quarter, and up 1032.83% compared to the same period a year ago.
Progyny Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $304.09M | 9.35% |
| 2024-03-31 | $278.08M | 3.01% |
| 2023-12-31 | $269.94M | -3.90% |
| 2023-09-30 | $280.89M | 0.54% |
| 2023-06-30 | $279.37M | 8.12% |
| 2023-03-31 | $258.39M | 20.56% |
| 2022-12-31 | $214.32M | 4.36% |
| 2022-09-30 | $205.37M | 5.32% |
| 2022-06-30 | $195.00M | 13.23% |
| 2022-03-31 | $172.22M | 35.02% |
| 2021-12-31 | $127.55M | 4.31% |
| 2021-09-30 | $122.28M | -4.95% |
| 2021-06-30 | $128.65M | 5.34% |
| 2021-03-31 | $122.13M | 21.77% |
| 2020-12-31 | $100.30M | 1.39% |
| 2020-09-30 | $98.93M | 53.13% |
| 2020-06-30 | $64.61M | -20.26% |
| 2020-03-31 | $81.02M | 24.42% |
| 2019-12-31 | $65.12M | 6.42% |
| 2019-09-30 | $61.20M | 8.95% |
| 2019-06-30 | $56.17M | 19.01% |
| 2019-03-31 | $47.20M | 61.71% |
| 2018-12-31 | $29.19M | 5.00% |
| 2018-09-30 | $27.80M | 6.27% |
| 2018-06-30 | $26.16M | 17.52% |
| 2018-03-31 | $22.26M | - |
Progyny generated $304.09M in revenue during Q2 2024, up 9.35% compared to the previous quarter, and up 117.68% compared to the same period a year ago.
Progyny Revenue Breakdown
Progyny Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Fertility benefit services revenue | $676.29M | $510.14M | $355.62M | - | - |
| Pharmacy benefit services revenue | $412.30M | $276.77M | $145.00M | - | - |
| Fertility Benefit Services | - | - | - | $253.56M | $189.62M |
| Pharmacy Benefit Services | - | - | - | $91.30M | $40.06M |
Progyny's latest annual revenue breakdown by segment (product or service), as of Dec 23: Fertility benefit services revenue (62.13%), and Pharmacy benefit services revenue (37.87%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacy benefit services revenue | $108.31M | $98.64M | $105.78M | $106.64M | $101.25M | $76.07M | $68.21M | $61.30M | $38.37M | $36.97M | $36.38M | - | - | - | - | - | - | - |
| Fertility benefit services revenue | $169.77M | $171.30M | $175.11M | $172.74M | $157.15M | $129.30M | $126.79M | $110.92M | $89.18M | $85.31M | $92.27M | - | - | - | - | - | - | - |
| Fertility Benefit Services | - | - | - | - | - | - | - | - | - | - | - | $88.85M | $74.71M | $73.14M | $46.27M | $59.43M | $53.53M | $50.02M |
| Pharmacy Benefit Services | - | - | - | - | - | - | - | - | - | - | - | $33.28M | $25.59M | $25.79M | $18.33M | $21.59M | $11.59M | $11.17M |
Progyny's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Fertility benefit services revenue (61.05%), and Pharmacy benefit services revenue (38.95%).
Progyny Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TDOC | Teladoc Health | $2.60B | $642.44M |
| VEEV | Veeva Systems | $2.36B | $650.35M |
| EVH | Evolent Health | $1.96B | $647.14M |
| PRVA | Privia Health Group | $1.66B | $422.33M |
| PGNY | Progyny | $1.09B | $304.09M |
| GDRX | GoodRx | $750.26M | $200.61M |
| TXG | 10x Genomics | $618.73M | $153.10M |
| PHR | Phreesia | $356.30M | $101.22M |
| CERT | Certara | $354.34M | $93.31M |
| HCAT | Health Catalyst | $295.94M | $74.72M |
| HSTM | HealthStream | $279.06M | $71.56M |
| DH | Definitive Healthcare | $251.41M | $63.70M |
| NRC | National Research | $148.58M | $35.31M |
| SLP | Simulations Plus | $59.58M | $18.54M |
PGNY Revenue FAQ
What is Progyny’s yearly revenue?
Progyny's yearly revenue for 2023 was $1.09B, representing an increase of 38.34% compared to 2022. The company's yearly revenue for 2022 was $786.91M, representing an increase of 57.19% compared to 2021. PGNY's yearly revenue for 2021 was $500.62M, representing an increase of 45.17% compared to 2020.
What is Progyny’s quarterly revenue?
Progyny's quarterly revenue for Q2 2024 was $304.09M, a 9.35% increase from the previous quarter (Q1 2024), and a 8.85% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $278.08M, a 3.01% increase from the previous quarter (Q4 2023), and a 7.62% increase year-over-year (Q1 2023). PGNY's quarterly revenue for Q4 2023 was $269.94M, a -3.90% decrease from the previous quarter (Q3 2023), and a 25.95% increase year-over-year (Q4 2022).
What is Progyny’s revenue growth rate?
Progyny's revenue growth rate for the last 3 years (2021-2023) was 117.45%, and for the last 5 years (2019-2023) was 373.96%.
What are Progyny’s revenue streams?
Progyny's revenue streams in c 23 are Fertility benefit services revenue, and Pharmacy benefit services revenue. Fertility benefit services revenue generated $676.3M in revenue, accounting 62.13% of the company's total revenue, up 32.57% year-over-year. Pharmacy benefit services revenue generated $412.3M in revenue, accounting 37.87% of the company's total revenue, up 48.97% year-over-year.
What is Progyny’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Progyny was Fertility benefit services revenue. This segment made a revenue of $676.3M, representing 62.13% of the company's total revenue.